Enveric Biosciences has announced the issuance of a new U.S. patent (USPTO Number 12,187,679) covering a novel family of molecules with potential applications in treating sleep and central nervous system $(CNS)$ disorders. This patent enhances the company's intellectual property portfolio and includes selective melatonin receptor-binding compounds, which could be used to target sleep disorders. Among the covered molecules are potential MT1-selective agonists, suggesting promise for innovative sleep therapeutics. The patent further supports Enveric's CNS-focused strategy, targeting high-value therapeutic markets.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。